RECOVERY & TISSUE REPAIR / FAQ
Questions From the Bench
Direct, citation-anchored answers to the questions readers most often bring to BPC-157, KLOW, KPV, and TB-500.
What does BPC-157 do in the body?
BPC-157 is studied in animal models for its role in tissue repair, with the best-documented action being angiogenesis: it up-regulates the VEGFR2 receptor and drives VEGFR2-Akt-eNOS signaling to build new blood vessels and speed blood flow to injured tissue [4]. The same body of research links it to accelerated gastric-ulcer healing, with an ulcer-inhibition ratio of 45.7-65.6% at higher doses in rats [5], and to proposed effects on tendon, ligament, and gut-lining repair via additional routes including the FAK-paxillin migration complex and growth-hormone-receptor sensitization in tendon cells. Nearly all of this evidence is preclinical; the only human data are a two-person IV safety pilot [1].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone and has no structural relationship to human growth hormone. It is a synthetic 15-amino-acid peptide derived from a partial sequence of a human gastric-juice protein. Where growth hormone comes up in the BPC-157 literature, it is because BPC-157 is reported to sensitize the growth-hormone receptor in cultured tendon fibroblasts, a proposed contributing mechanism in tendon repair, not evidence that BPC-157 itself acts as a hormone or raises growth-hormone levels.
Does BPC-157 work immediately?
There is no controlled human trial measuring how quickly BPC-157 acts, so no timeline can be cited as established fact. In research communities, this is anecdotal, not clinical evidence: people report tendon, ligament, and joint improvements becoming noticeable within one to three weeks, and digestive or gut-comfort changes within one to two weeks. These are self-reported timelines from online communities, not measurements from a controlled study, and they vary considerably between individuals.
Does BPC-157 damage the liver?
The only human safety data available found no evidence of liver harm: a 2025 pilot giving two healthy adults intravenous BPC-157 up to 20 mg found no measurable changes in hepatic (liver) biomarkers, alongside no changes in cardiac, renal, thyroid, or glucose markers [1]. That said, an n of two cannot rule out rare or longer-term liver effects, and no larger human safety trial has been conducted.
What is KLOW peptide?
KLOW is a co-formulated research vial containing four separate peptides, most commonly listed as GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg in an 80 mg total vial. The four peptides are simply co-dissolved together, not chemically bonded into one molecule, and each carries its own separate research literature. No FDA-approved or pharmacopeial combination product under this name exists.
What is KLOW peptide used for?
KLOW is marketed by research-chemical vendors for tissue repair broadly, combining the angiogenesis focus of BPC-157, the cell-migration mechanism of TB-500, the anti-inflammatory action of KPV, and the matrix-synthesis effects of GHK-Cu. No study has tested the blend itself for any application; every use case attached to KLOW is inherited from its four individual ingredients' separate literatures, not from a blend-specific trial.
Where do you inject KLOW peptide?
This notebook does not provide administration guidance for any compound, including KLOW. Published research on KLOW's individual components has used routes such as intravenous and intramuscular delivery for BPC-157 [1][3] and intravenous delivery for full-length thymosin beta-4 [16], but these describe how researchers administered specific doses in specific studies, not a recommendation for any person. KLOW is sold for laboratory research use only.
How much KLOW peptide per day?
No controlled human dosing study of KLOW exists, so there is no evidence-based daily amount to report, and this notebook does not recommend one. For context on what has actually been studied: the BPC-157 pilot used a single intravenous dose up to 20 mg in two people [1], and the full-length thymosin beta-4 Phase 1 trial used daily intravenous doses up to 1260 mg for 14 days in a clinical-research setting [16], figures from specific cited studies of single ingredients, not dosing guidance for KLOW.
What is KPV peptide?
KPV is a linear tripeptide, Lys-Pro-Val (molecular formula C16H30N4O4), corresponding to the final three amino acids (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains alpha-MSH's anti-inflammatory signaling while lacking its pigment-darkening effect [13].
What does KPV peptide do?
In laboratory and mouse studies, KPV suppresses NF-kB and MAP-kinase inflammatory signaling and reduces secretion of pro-inflammatory cytokines. In gut tissue specifically, it is taken up directly into epithelial cells via the PepT1 transporter, which is itself more active in inflamed intestinal tissue [9]. There are no published human studies confirming these effects in people.
What is KPV peptide used for?
KPV's research literature is almost entirely about gut inflammation: it has reduced disease severity in multiple mouse models of colitis, including DSS-induced and CD45RB-hi adoptive-transfer colitis [9][12], and newer delivery-focused studies have used nanoparticle and hydrogel formulations to get more intact KPV to inflamed colon tissue [10][11]. All of this evidence is preclinical; no human trial has tested KPV for any use.
What is KPV peptide good for?
Based on the cited animal and cell-culture literature, KPV is studied specifically for calming inflammatory signaling in the gut, reducing colitis severity, myeloperoxidase activity, and inflammatory infiltrate in mouse models [9][12]. It is not studied as a general wellness or skin compound in the peer-reviewed literature reviewed for this notebook; claims beyond gut-inflammation research outrun the evidence.
What is TB-500?
TB-500 is a synthetic, N-acetylated seven-amino-acid peptide (Ac-LKKTETQ) corresponding to residues 17-23 of the naturally occurring 43-amino-acid protein thymosin beta-4. That short stretch carries thymosin beta-4's actin-binding motif [17]. Most of the encouraging published research behind TB-500's reputation actually used the full-length protein, not this fragment.
What does TB-500 stand for and what does TB stand for in TB-500?
'TB' in TB-500 is shorthand drawn from 'Thymosin Beta,' reflecting that the compound is a synthetic fragment of the protein Thymosin Beta-4. The corpus behind this notebook did not find a documented, peer-reviewed origin for the specific number '500' in the name; it functions as a research-community and commercial designation rather than a scientific measurement, so this notebook does not assert a definitive etymology beyond the Thymosin Beta connection.
What is TB-500 used for in research?
Research using the thymosin beta-4 pathway, chiefly the full-length protein, has studied wound healing, where topical or systemic Tβ4 increased re-epithelialization by 42-61% versus saline in rats [19], cardiac repair after induced ischemia in mice [18], and post-stroke neurological recovery in rats, where 2 and 12 mg/kg improved outcomes but 18 mg/kg did not [14]. A 2010 Phase 1 trial established the full-length protein was well tolerated intravenously up to 1260 mg over 14 days in 40 healthy volunteers [16]. None of this directly tested the 7-amino-acid fragment sold as TB-500.
Does TB-500 work for muscle tears and recovery from exercise?
No completed human trial has tested TB-500, the fragment, for muscle tears or exercise recovery specifically. In research communities, this is anecdotal, not clinical evidence: people frequently report faster recovery from tendon, ligament, and muscle injuries, and improved flexibility and mobility, often noticing changes around three to four weeks in. The proposed mechanism, actin-binding cell migration, which the fragment is designed to carry, is mechanistically plausible for muscle repair based on how full-length thymosin beta-4 behaves in animal wound and cardiac models [17][18][19], but this has not been confirmed in a controlled human study of muscle injury specifically.